CE3F4 - CAS 143703-25-7
Category: Inhibitor
Please be kindly noted products are not for therapeutic use. We do not sell to patients.
Molecular Formula:
C11H10Br2FNO
Molecular Weight:
351.01
COA:
Inquire
Targets:
Others
Description:
CE3F4 is a noncompetitive Epac1 inhibitor that inhibits Epac-induced Rap activation and prevents isoprenaline-induced autophagy flux in cardiomyocytes. It has no effect on PKA activity in the presence of cAMP.
Brife Description:
Epac1 inhibitor
Purity:
≥98% by HPLC
Synonyms:
CE3F4; CE-3-F-4; CE 3 F 4; CE-3F4; CE 3F4; 5,7-Dibromo-6-fluoro-3,4-dihydro-2-methyl-1(2H)-quinolinecarboxaldehyde
MSDS:
Inquire
InChIKey:
ZZLQPWXVZCPUGC-UHFFFAOYSA-N
InChI:
InChI=1S/C11H10Br2FNO/c1-6-2-3-7-9(15(6)5-16)4-8(12)11(14)10(7)13/h4-6H,2-3H2,1H3
Canonical SMILES:
CC1CCC2=C(C(=C(C=C2N1C=O)Br)F)Br
1.Activation of G protein-coupled estrogen receptor 1 induces coronary artery relaxation via Epac/Rap1-mediated inhibition of RhoA/Rho kinase pathway in parallel with PKA.
Yu X;Zhang Q;Zhao Y;Schwarz BJ;Stallone JN;Heaps CL;Han G PLoS One. 2017 Mar 9;12(3):e0173085. doi: 10.1371/journal.pone.0173085. eCollection 2017.
Previously, we reported that cAMP/PKA signaling is involved in GPER-mediated coronary relaxation by activating MLCP via inhibition of RhoA pathway. In the current study, we tested the hypothesis that activation of GPER induces coronary artery relaxation via inhibition of RhoA/Rho kinase pathway by cAMP downstream targets, exchange proteins directly activated by cAMP (Epac) as well as PKA. Our results show that Epac inhibitors, brefeldin A (BFA, 50 μM), or ESI-09 (20 μM), or CE3F4 (100 μM), all partially inhibited porcine coronary artery relaxation response to the selective GPER agonist, G-1 (0.3-3 μM); while concurrent administration of BFA and PKI (5 μM), a PKA inhibitor, almost completely blocked the relaxation effect of G-1. The Epac specific agonist, 8-CPT-2Me-cAMP (007, 1-100 μM), induced a concentration-dependent relaxation response. Furthermore, the activity of Ras-related protein 1 (Rap1) was up regulated by G-1 (1 μM) treatment of porcine coronary artery smooth muscle cells (CASMCs). Phosphorylation of vasodilator-stimulated phosphoprotein (p-VASP) was elevated by G-1 (1 μM) treatment, but not by 007 (50 μM); and the effect of G-1 on p-VASP was blocked by PKI, but not by ESI-09, an Epac antagonist.
2.Identification and validation of modulators of exchange protein activated by cAMP (Epac) activity: structure-function implications for Epac activation and inhibition.
Brown LM;Rogers KE;McCammon JA;Insel PA J Biol Chem. 2014 Mar 21;289(12):8217-30. doi: 10.1074/jbc.M114.548636. Epub 2014 Feb 4.
The signaling molecule cAMP primarily mediates its effects by activating PKA and/or exchange protein activated by cAMP (Epac). Epac has been implicated in many responses in cells, but its precise roles have been difficult to define in the absence of Epac inhibitors. Epac, a guanine nucleotide exchange factor for the low molecular weight G protein Rap, is directly activated by cAMP. Using a bioluminescence resonance energy transfer-based assay (CAMYEL) to examine modulators of Epac activity, we took advantage of its intramolecular movement that occurs upon cAMP binding to assess Epac activation. We found that the use of CAMYEL can detect the binding of cAMP analogs to Epac and their modulation of its activity and can distinguish between agonists (cAMP), partial agonists (8-chlorophenylthio-cAMP), and super agonists (8-chlorophenylthio-2'-O-Me-cAMP). The CAMYEL assay can also identify competitive and uncompetitive Epac inhibitors, e.g. (Rp)-cAMPS and CE3F4, respectively. To confirm the results with the CAMYEL assay, we used Swiss 3T3 cells and assessed the ability of cyclic nucleotide analogs to modulate the activity of Epac or PKA, determined by Rap1 activity or VASP phosphorylation, respectively.
3.Exchange protein directly activated by cAMP 1 promotes autophagy during cardiomyocyte hypertrophy.
Laurent AC;Bisserier M;Lucas A;Tortosa F;Roumieux M;De Régibus A;Swiader A;Sainte-Marie Y;Heymes C;Vindis C;Lezoualc'h F Cardiovasc Res. 2015 Jan 1;105(1):55-64. doi: 10.1093/cvr/cvu242. Epub 2014 Nov 19.
AIMS: ;Stimulation of β-adrenergic receptors (β-AR) increases cAMP production and contributes to the pathogenesis of cardiac hypertrophy and failure through poorly understood mechanisms. We previously demonstrated that Exchange protein directly activated by cAMP 1 (Epac1)-induced hypertrophy in primary cardiomyocytes. Among the mechanisms triggered by cardiac stress, autophagy has been highlighted as a protective or harmful response. Here, we investigate whether Epac1 promotes cardiac autophagy and how altered autophagy has an impact on Epac1-induced cardiomyocyte hypertrophy.;METHODS AND RESULTS: ;We reported that direct stimulation of Epac1 with the agonist, Sp-8-(4-chlorophenylthio)-2'-O-methyl-cAMP (Sp-8-pCPT) promoted autophagy activation in neonatal cardiomyocytes. Stimulation of β-AR with isoprenaline (ISO) mimicked the effect of Epac1 on autophagy markers. Conversely, the induction of autophagy flux following ISO treatment was prevented in cardiomyocytes pre-treated with a selective inhibitor of Epac1, CE3F4. Importantly, we found that Epac1 deletion in mice protected against β-AR-induced cardiac remodelling and prevented the induction of autophagy. The signalling mechanisms underlying Epac1-induced autophagy involved a Ca(2+)/calmodulin-dependent kinase kinase β (CaMKKβ)/AMP-dependent protein kinase (AMPK) pathway.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related Products


CAS 53963-43-2 Ginsenoside F1

Ginsenoside F1
(CAS: 53963-43-2)

Ginsenoside F1, a metabolite of ginsenoside Rg1, which is used as an aldose reductase inhibitor and my exert anti-inflammatory and immunomodulatory activity.

CP-67804
(CAS: 103978-08-1)

CP-67804 enhances topoisomerase II-mediated DNA cleavage. It represent a novel class of topoisomerase II-targeted drugs which have potential as antineoplastic a...

CAS 957230-65-8 Isofagomine D-Tartrate

Isofagomine D-Tartrate
(CAS: 957230-65-8)

The D-Tartrate salt form of Isofagomine, an imino pyranose compound, has been found to be a glucosylceramidase stimulant and could exhibit activity in Gaucher's...

CAS 439571-48-9 NDT 9513727

NDT 9513727
(CAS: 439571-48-9)

NDT 9513727 is a C5a receptor (C5aR) antagonist with IC50 value of 11.6 nM. NDT 9513727 can inhibit C5a-induced neutropenia in gerbil and cynomolgus macaque. In...

PD-116779
(CAS: 102674-89-5)

PD-116779 is a novle antitumor antibiotic belonging the benz[a]anthraquinone class.

CAS 890819-86-0 ML 349

ML 349
(CAS: 890819-86-0)

ML 349 is a lysophospholipase 2 inhibitor with IC50 value of 144 nM.

CAS 82801-73-8 PKG Inhibitor

PKG Inhibitor
(CAS: 82801-73-8)

PKG Inhibitor is a competitive inhibitor of cGMP-dependent protein kinase (PKG). It is an analog of a substrate peptide corresponding to a phosphorylation site ...

CAS 905-99-7 Cryptochlorogenic acid

Cryptochlorogenic acid
(CAS: 905-99-7)

Cryptochlorogenic acid is an isomer of chlorogenic acid. It is a natural product extracted from the flowerbud of Lonicera japonica Thunb. It has antioxidant act...

Chemical Structure

CAS 143703-25-7 CE3F4

Quick Inquiry

Verification code

Featured Items